AbCellera
Company type | Public |
---|---|
Nasdaq: ABCL | |
Industry | Biotechnology |
Founded | 2012 |
Headquarters | Vancouver, British Columbia |
Revenue | 375.2 million (2021) |
Number of employees | 386 (2021) |
Website | www |
AbCellera Biologics Inc. is a
History
AbCellera was founded in 2012 by biomedical researchers Carl Hansen, Véronique Lecault, Kevin Heyries, Daniel Da Costa and Oleh Petriv. In November 2016, the company received a US$645K grant from the
In January 2017, AbCellera announced that it would be collaborating with Pfizer to discover and develop antibodies against "undisclosed membrane protein targets.”[8][9]
COVID-19 and expansion
In June 2020, AbCellera announced it had begun the world's first study of a potential
In September 2021, the company announced a multi-year agreement with Moderna to develop mRNA-based antibody treatments against multiple diseases.[16]
In January 2022, the company received a $1.5 million grant from the Bill & Melinda Gates Foundation to identify
Other partnerships include collaborations with
See also
References
- ^ Niiler, Eric (2020-02-14). "Darpa Cranks Up Antibody Research to Stall Coronavirus". Wired. Condé Nast. Retrieved 2020-02-16.
- ^ Cumbers, John (2020-02-05). "The Synthetic Biology Companies Racing To Fight Coronavirus". Forbes. Retrieved 2020-02-16.
- ^ Shore, Randy (2017-03-03). "B.C.'s biotech leaders are growing up and going global". Vancouver Sun. Postmedia Network. Retrieved 2020-02-16.
- ^ "Grant: AbCellera Biologics Inc". Bill & Melinda Gates Foundation. November 2016. Archived from the original on 2022-05-04. Retrieved 2020-02-16.
- ^ McGrane, Clare (2018-09-27). "AbCellera raises $10M for machine-learning fueled antibody discovery platform". GeekWire. Retrieved 2020-02-16.
- ISSN 0099-9660. Retrieved 2020-07-21.
- ^ Knapp, Alex. "AbCellera Raises $105 Million To Boost Drug Discovery Against Coronavirus And Other Diseases". Forbes. Retrieved 2020-07-21.
- ^ Heyries, Kevin (2017-01-05). "AbCellera Announces Multi-Target Research Collaboration with Pfizer". AbCellera. Archived from the original on 2022-05-04. Retrieved 2022-05-04.
- ^ "Research programme: transmembrane protein modulators - AbCellera/Pfizer". Adis Insight - Springer Science+Business Media. 2021-02-28. Archived from the original on 2022-05-04. Retrieved 2022-05-04.
- ^ "Lilly Begins World's First Study of a Potential COVID-19 Antibody Treatment in Humans". Lilly. 1 June 2020. Retrieved 4 June 2020.
- PMID 33306087.
- U.S. Food & Drug Administration. Archivedfrom the original on 2022-04-06. Retrieved 2022-05-04.
- U.S. Food & Drug Administration. Archivedfrom the original on 2021-05-27. Retrieved 2022-05-04.
- ^ Mayani, Mamta (2020-12-29). "Peter Thiel reports 5.3% stake in AbCellera Bio (NASDAQ:ABCL)". Seeking Alpha. Archived from the original on 2022-05-04. Retrieved 2022-05-04.
- ^ Yingling, Jessica (2020-11-19). "Peter Thiel Joins AbCellera's Board of Directors". AbCellera. Archived from the original on 2022-05-04. Retrieved 2022-05-04.
- ^ Khandekar, Amruta (2021-09-15). "AbCellera and Moderna team up to develop antibody therapies". Reuters. Retrieved 2022-05-04.
- ^ "AbCellera Biologics Inc". Bill & Melinda Gates Foundation. January 2022. Archived from the original on 2022-05-04. Retrieved 2022-05-04.
- ^ Tong, Amber (2022-02-14). "As Omicron rages, FDA clears Eli Lilly/AbCellera's new antibody days after $720M supply deal". Endpoints News. Archived from the original on 2022-02-15. Retrieved 2022-05-04.
- ^ "AbCellera collaborates with Novartis for antibody discovery". PharmaTimes. 2019-02-14. Retrieved 2020-02-16.
- ^ "Partnership". AbCellera. Archived from the original on 2022-05-04. Retrieved 2022-05-04.